search
Back to results

The Diaphragmatic Initiated Ventilatory Assist (DIVA) Trial (DIVA)

Primary Purpose

Extubation Failure, Bronchopulmonary Dysplasia, Death

Status
Recruiting
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
NIV-NAVA
NS-NIPPV
Sponsored by
University of Pennsylvania
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Extubation Failure

Eligibility Criteria

0 Days - 28 Days (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Gestational age of 24-27 6/7 weeks at birth
  • Intubated in the first 7 days of life
  • Undergoing extubation following at least 12 hours of invasive mechanical ventilation
  • Post-natal age <28 days at time of extubation

Exclusion Criteria:

  • Major congenital anomalies, including pulmonary hypoplasia
  • Neurologic disorders affecting respiratory drive (other than apnea of prematurity)
  • Esophageal bleeding or other contraindication to NG/OG catheter placement
  • Current weight <500 grams (based on Edi catheter approval)
  • Study ventilator not available at time eligibility criteria are met
  • Planned surgery or invasive procedure within 5 days of extubation
  • Informed consent not provided

Sites / Locations

  • Arkansas Children's HospitalRecruiting
  • Loma Linda University
  • Sharp Mary Birch
  • Joe DiMaggio Children's HospitalRecruiting
  • Peyton Manning Children's HospitalRecruiting
  • Norton Children's HospitalRecruiting
  • Children's Mercy HospitalRecruiting
  • Hospital of the University of PennsylvaniaRecruiting
  • Intermountain Medical Center
  • Children's Hospital of Richmond
  • Mt Sinai HospitalRecruiting
  • BC Children's and Women's Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

NIV-NAVA

NS- NIPPV

Arm Description

Outcomes

Primary Outcome Measures

Extubation failure
Extubation failure is defined when an infant is on the allocated mode of respiratory support and meets any of the following 4 criteria: (1) Rise in FiO2 at least 20% from pre-extubation value for >2 hours to maintain local SpO2 targets, (2) pH ≤7.20 or pCO2 ≥70mm Hg; (3) >1 apneic event requiring positive pressure ventilation (PPV) within 6 hours or ≥ 6 apneic events requiring stimulation within 6 hours (4) emergent intubation by the clinical team for cardiovascular instability or surgery.

Secondary Outcome Measures

Bronchopulmonary Dysplasia (BPD) at 36 weeks PMA
BPD will be assessed as an ordinal outcome (none, grade 1, 2, 3), according to the NRN criteria.
Death or BPD at 36 weeks PMA
Composite dichotomous (y/n) outcome of death or grade 2/3 BPD, using the NRN criteria
Endotracheal intubation through 36 weeks PMA
Endotracheal intubation will be assessed 2 ways: As a dichotomous (y/n) outcome if it occurs at any time and also as days until endotracheal intubation (with censoring at 36 weeks PMA)
Postmenstrual age at last invasive ventilation
Time to cessation of invasive ventilation, with censoring at 36 weeks PMA
Postmenstrual age at last positive pressure support
Time to cessation of positive pressure respiratory support, with censoring at 36 weeks PMA
Postmenstrual age at last supplemental oxygen
Time to cessation of supplemental oxygen, with censoring at 36 weeks PMA
Prematurity-related morbidities through 36 weeks PMA
Brain injury (intraventricular hemorrhage and periventricular leukomalacia), patent ductus arteriosus requiring therapy, pulmonary hemorrhage, culture proven sepsis, necrotizing enterocolitis, retinopathy of prematurity

Full Information

First Posted
June 28, 2022
Last Updated
February 14, 2023
Sponsor
University of Pennsylvania
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
search

1. Study Identification

Unique Protocol Identification Number
NCT05446272
Brief Title
The Diaphragmatic Initiated Ventilatory Assist (DIVA) Trial
Acronym
DIVA
Official Title
The Diaphragmatic Initiated Ventilatory Assist (DIVA) Trial
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Recruiting
Study Start Date
August 3, 2022 (Actual)
Primary Completion Date
March 31, 2026 (Anticipated)
Study Completion Date
March 31, 2027 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Pennsylvania
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
DIVA is a pragmatic randomized clinical trial (RCT) to determine: among (P) preterm infants born 24-27 6/7 weeks gestation undergoing extubation from mechanical ventilation, whether (I) Non-invasive neurally adjusted ventilatory assist (NIV-NAVA) (C) compared with Non-synchronized nasal intermittent positive pressure ventilation (NS-NIPPV), will reduce the incidence of (O) extubation failure within (T) 5 days (120 hours) of extubation.
Detailed Description
Bronchopulmonary dysplasia (BPD) is the most common complication of prematurity and is the leading respiratory cause of childhood morbidity. Ventilator induced lung injury (VILI) an accepted and important contributor to BPD. Exposure to oxygen and positive pressure ventilation leads to developmental arrest and parenchymal injury in the immature preterm lung. Because even brief exposure to intubated positive pressure ventilation is injurious, avoiding invasive mechanical ventilation is the most widely acknowledged strategy to prevent VILI and the long-term sequela of BPD. Therefore, time on ventilators and rates of successful extubation are important endpoints of therapy. Non-invasive neurally adjusted ventilatory assist (NIV-NAVA) is an FDA approved technology that consistently synchronizes non-invasive respiratory support with infant respiratory drive. The Diaphragmatic Initiated Ventilatory Assist (DIVA) trial is an unblinded, pragmatic, multicenter phase III randomized clinical trial in extremely preterm infants 240/7- 276/7 weeks gestational age to determine if NIV-NAVA, compared with non-synchronized nasal intermittent positive pressure ventilation (NS-NIPPV), prevents extubation failure within 5 days (120 hours) of extubation from mechanical ventilation

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Extubation Failure, Bronchopulmonary Dysplasia, Death

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Investigator
Masking Description
Trial PIs are unaware of treatment allocation for individual subjects
Allocation
Randomized
Enrollment
478 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
NIV-NAVA
Arm Type
Experimental
Arm Title
NS- NIPPV
Arm Type
Active Comparator
Intervention Type
Device
Intervention Name(s)
NIV-NAVA
Other Intervention Name(s)
Non-invasive Neurally Adjusted Ventilatory Assist
Intervention Description
Infants in the intervention arm will be managed with non-invasive neurally adjusted ventilatory assist (NIV-NAVA) using FDA-approved servos with associated FDA-approved Edi catheter.
Intervention Type
Device
Intervention Name(s)
NS-NIPPV
Other Intervention Name(s)
Non-synchronized Non-invasive Positive Pressure Ventilation
Intervention Description
Infants in the active comparator arm will be treated with non-synchronized non-invasive positive pressure ventilation (NIPPV) through FDA-approved ventilators currently in use at each site.
Primary Outcome Measure Information:
Title
Extubation failure
Description
Extubation failure is defined when an infant is on the allocated mode of respiratory support and meets any of the following 4 criteria: (1) Rise in FiO2 at least 20% from pre-extubation value for >2 hours to maintain local SpO2 targets, (2) pH ≤7.20 or pCO2 ≥70mm Hg; (3) >1 apneic event requiring positive pressure ventilation (PPV) within 6 hours or ≥ 6 apneic events requiring stimulation within 6 hours (4) emergent intubation by the clinical team for cardiovascular instability or surgery.
Time Frame
within the first 5 days (120 hours) post extubation
Secondary Outcome Measure Information:
Title
Bronchopulmonary Dysplasia (BPD) at 36 weeks PMA
Description
BPD will be assessed as an ordinal outcome (none, grade 1, 2, 3), according to the NRN criteria.
Time Frame
36 weeks PMA
Title
Death or BPD at 36 weeks PMA
Description
Composite dichotomous (y/n) outcome of death or grade 2/3 BPD, using the NRN criteria
Time Frame
36 weeks PMA
Title
Endotracheal intubation through 36 weeks PMA
Description
Endotracheal intubation will be assessed 2 ways: As a dichotomous (y/n) outcome if it occurs at any time and also as days until endotracheal intubation (with censoring at 36 weeks PMA)
Time Frame
36 weeks PMA
Title
Postmenstrual age at last invasive ventilation
Description
Time to cessation of invasive ventilation, with censoring at 36 weeks PMA
Time Frame
36 weeks PMA
Title
Postmenstrual age at last positive pressure support
Description
Time to cessation of positive pressure respiratory support, with censoring at 36 weeks PMA
Time Frame
36 weeks PMA
Title
Postmenstrual age at last supplemental oxygen
Description
Time to cessation of supplemental oxygen, with censoring at 36 weeks PMA
Time Frame
36 weeks PMA
Title
Prematurity-related morbidities through 36 weeks PMA
Description
Brain injury (intraventricular hemorrhage and periventricular leukomalacia), patent ductus arteriosus requiring therapy, pulmonary hemorrhage, culture proven sepsis, necrotizing enterocolitis, retinopathy of prematurity
Time Frame
36 weeks PMA
Other Pre-specified Outcome Measures:
Title
Death
Description
Death will be measured in two ways (1) as a dichotomous (y/n) outcome if death occurs prior to 36 weeks PMA, and (2) days until death (with censoring at 36 weeks PMA).
Time Frame
From randomization through 36 weeks PMA
Title
Air Leaks
Description
Air leaks will be measured as a dichotomous (y/n) outcome if a new pulmonary interstitial emphysema or pneumothorax occurs at any time after randomization until 36 weeks PMA.
Time Frame
From randomization through 36 weeks PMA
Title
Gastrointestinal perforation or bleeding
Description
This will be measured as a dichotomous (y/n) outcome if a new GI perforation or bleeding occurs at any time after randomization until 36 weeks PMA.
Time Frame
From randomization through 36 weeks PMA

10. Eligibility

Sex
All
Minimum Age & Unit of Time
0 Days
Maximum Age & Unit of Time
28 Days
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Gestational age of 24-27 6/7 weeks at birth Intubated in the first 7 days of life Undergoing extubation following at least 12 hours of invasive mechanical ventilation Post-natal age <28 days at time of extubation Exclusion Criteria: Major congenital anomalies, including pulmonary hypoplasia Neurologic disorders affecting respiratory drive (other than apnea of prematurity) Esophageal bleeding or other contraindication to NG/OG catheter placement Current weight <500 grams (based on Edi catheter approval) Study ventilator not available at time eligibility criteria are met Planned surgery or invasive procedure within 5 days of extubation Informed consent not provided
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Elizabeth Foglia
Phone
267-441-7144
Email
FOGLIA@email.chop.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Melissa Fernando
Phone
2157466145
Email
fernand@pennmedicine.upenn.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Elizabeth Foglia
Organizational Affiliation
CHOP/UPENN
Official's Role
Principal Investigator
Facility Information:
Facility Name
Arkansas Children's Hospital
City
Little Rock
State/Province
Arkansas
ZIP/Postal Code
72202
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
David Matlock
Email
DMatlock@uams.edu
Facility Name
Loma Linda University
City
Loma Linda
State/Province
California
ZIP/Postal Code
92350
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mitchell Goldstein
Email
MGoldstein@llu.edu
Facility Name
Sharp Mary Birch
City
San Diego
State/Province
California
ZIP/Postal Code
92123
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anup Katheria
Email
Anup.Katheria@sharp.com
Facility Name
Joe DiMaggio Children's Hospital
City
Hollywood
State/Province
Florida
ZIP/Postal Code
33021
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bruce Shulman
Email
brucesmd@icloud.com
Facility Name
Peyton Manning Children's Hospital
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46260
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Markus Tauscher
Email
mktausc1@ascension.org
Facility Name
Norton Children's Hospital
City
Louisville
State/Province
Kentucky
ZIP/Postal Code
40202
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dan Stewart
Email
dan.stewart@louisville.edu
Facility Name
Children's Mercy Hospital
City
Kansas City
State/Province
Missouri
ZIP/Postal Code
64108
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christopher Nitkin
Email
crnitkin@cmh.edu
Facility Name
Hospital of the University of Pennsylvania
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Elizabeth Foglia
Email
FOGLIA@email.chop.edu
Facility Name
Intermountain Medical Center
City
Murray
State/Province
Utah
ZIP/Postal Code
84107
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bradley Yoder
Email
Bradley.Yoder@hsc.utah.edu
Facility Name
Children's Hospital of Richmond
City
Richmond
State/Province
Virginia
ZIP/Postal Code
23219
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Karen Hendrick-Munoz
Email
karen.hendricks-munoz@vcuhealth.org
Facility Name
Mt Sinai Hospital
City
Toronto
ZIP/Postal Code
ON M5G 1X5
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Amish Jain
Email
Amish.Jain@sinaihealth.ca
Facility Name
BC Children's and Women's Hospital
City
Vancouver
ZIP/Postal Code
BC V6H 3N1
Country
Canada
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jonathan Wong
Email
jonathan.wong@cw.bc.ca

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Research records will be retained at each study site, and at the DCC for 3 years after completion of the study. We will follow NIH sharing policies with regards to sharing of data and specimens to public repositories, where appropriate
IPD Sharing Time Frame
3 years after completion of the study

Learn more about this trial

The Diaphragmatic Initiated Ventilatory Assist (DIVA) Trial

We'll reach out to this number within 24 hrs